caa a22 4500 605491275 CHVBK 20210128100509.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s10147-014-0766-3 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0766-3 Timing and characteristics of radiation pneumonitis after stereotactic body radiotherapy for peripherally located stage I lung cancer [Elektronische Daten] [Ayae Kanemoto, Yasuo Matsumoto, Tadashi Sugita] Background: This study was conducted to determine the timing and characteristics of radiation pneumonitis (RP) associated with stereotactic body radiotherapy (SBRT) for stage I lung cancer. Methods: Two hundred thirty-one patients treated with SBRT using 52Gy in 4 fractions were identified. Control rate, RP incidence rate, and predictive factors and timing of RP were evaluated retrospectively. Results: The 3-year overall survival and local control rates were 80.7 and 92.0%, respectively. The grade ≥2 RP rate was 13.0%; no grade 4-5 RP occurred. The most statistically significant predictive factor of grade ≥2 RP was V10. The median intervals to first graphical appearance were 4.2 and 2.5months for grade 1 and grade 2-3 RP, respectively. Median intervals to maximum radiological density change were 6.0 and 4.6months for grade 1 and grade 2-3 RP, respectively. A significantly different interval to first graphical appearance between grade 1 and grade 2-3 RP was observed; no significantly different interval to maximum radiological density change was noted. Conclusions: The first graphical appearance of grade ≥2 RP was earlier than that of grade 1 RP, although the timing of maximum radiological density change was not significantly different. Japan Society of Clinical Oncology, 2014 Stage I lung cancer nationallicence Stereotactic body radiotherapy nationallicence Radiation pneumonitis nationallicence Timing nationallicence Predictive factor nationallicence Kanemoto Ayae Department of Radiation Oncology, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, 951-8566, Niigata, Japan aut Matsumoto Yasuo Department of Radiation Oncology, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, 951-8566, Niigata, Japan aut Sugita Tadashi Department of Radiation Oncology, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, 951-8566, Niigata, Japan aut International Journal of Clinical Oncology Springer Japan 20/4(2015-08-01), 680-685 1341-9625 20:4<680 2015 20 10147 https://doi.org/10.1007/s10147-014-0766-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0766-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kanemoto Ayae Department of Radiation Oncology, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, 951-8566, Niigata, Japan aut NATIONALLICENCE 700 1- Matsumoto Yasuo Department of Radiation Oncology, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, 951-8566, Niigata, Japan aut NATIONALLICENCE 700 1- Sugita Tadashi Department of Radiation Oncology, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, 951-8566, Niigata, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/4(2015-08-01), 680-685 1341-9625 20:4<680 2015 20 10147